Real-world study of next-generation sequencing diagnostic biomarker testing for patients with lung cancer in Japan.

ABSTRACT: Our previous real-world studies raised concerns that sequential biomarker testing may lead to increased time to treatment when compared with simultaneous single biomarker testing. The Oncomine Dx target test (ODxTT), a next-generation sequencing-based multiplex biomarker panel test approved in Japan in 2019, is expected to improve time to treatment due to changes in testing methods. This retrospective observational study examined data claims for reimbursement submitted for patients with lung cancer in Japan between June 1, 2019, and March 31, 2020. To evaluate the change in testing prevalence over time and associated improvements in time to treatment, descriptive statistics were used to characterize biomarker testing patterns and rates and evaluate the time to treatment in the time followi

SUBMITTER: Takahashi T 

PROVIDER: S-EPMC10236614 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature